The Chinese Society of Clinical Oncology (CSCO) : Clinical guidelines for the diagnosis and treatment of gastric cancer, 2023
© 2023 The Authors. Cancer Communications published by John Wiley & Sons Australia, Ltd. on behalf of Sun Yat-sen University Cancer Center..
The 2023 update of the Chinese Society of Clinical Oncology (CSCO) Clinical Guidelines for Gastric Cancer focuses on standardizing cancer diagnosis and treatment in China, reflecting the latest advancements in evidence-based medicine, healthcare resource availability, and precision medicine. These updates address the differences in epidemiological characteristics, clinicopathological features, tumor biology, treatment patterns, and drug selections between Eastern and Western gastric cancer patients. Key revisions include a structured template for imaging diagnosis reports, updated standards for molecular marker testing in pathological diagnosis, and an elevated recommendation for neoadjuvant chemotherapy in stage III gastric cancer. For advanced metastatic gastric cancer, the guidelines introduce new recommendations for immunotherapy, anti-angiogenic therapy and targeted drugs, along with updated management strategies for human epidermal growth factor receptor 2 (HER2)-positive and deficient DNA mismatch repair (dMMR)/microsatellite instability-high (MSI-H) patients. Additionally, the guidelines offer detailed screening recommendations for hereditary gastric cancer and an appendix listing drug treatment regimens for various stages of gastric cancer. The 2023 CSCO Clinical Guidelines for Gastric Cancer updates are based on both Chinese and international clinical research and expert consensus to enhance their applicability and relevance in clinical practice, particularly in the heterogeneous healthcare landscape of China, while maintaining a commitment to scientific rigor, impartiality, and timely revisions.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:44 |
|---|---|
| Enthalten in: |
Cancer communications (London, England) - 44(2024), 1 vom: 23. Jan., Seite 127-172 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Wang, Feng-Hua [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Adjuvant |
|---|
| Anmerkungen: |
Date Completed 19.01.2024 Date Revised 13.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/cac2.12516 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM366509748 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366509748 | ||
| 003 | DE-627 | ||
| 005 | 20240313234008.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240108s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/cac2.12516 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1326.xml |
| 035 | |a (DE-627)NLM366509748 | ||
| 035 | |a (NLM)38160327 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Wang, Feng-Hua |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The Chinese Society of Clinical Oncology (CSCO) |b Clinical guidelines for the diagnosis and treatment of gastric cancer, 2023 |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.01.2024 | ||
| 500 | |a Date Revised 13.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 The Authors. Cancer Communications published by John Wiley & Sons Australia, Ltd. on behalf of Sun Yat-sen University Cancer Center. | ||
| 520 | |a The 2023 update of the Chinese Society of Clinical Oncology (CSCO) Clinical Guidelines for Gastric Cancer focuses on standardizing cancer diagnosis and treatment in China, reflecting the latest advancements in evidence-based medicine, healthcare resource availability, and precision medicine. These updates address the differences in epidemiological characteristics, clinicopathological features, tumor biology, treatment patterns, and drug selections between Eastern and Western gastric cancer patients. Key revisions include a structured template for imaging diagnosis reports, updated standards for molecular marker testing in pathological diagnosis, and an elevated recommendation for neoadjuvant chemotherapy in stage III gastric cancer. For advanced metastatic gastric cancer, the guidelines introduce new recommendations for immunotherapy, anti-angiogenic therapy and targeted drugs, along with updated management strategies for human epidermal growth factor receptor 2 (HER2)-positive and deficient DNA mismatch repair (dMMR)/microsatellite instability-high (MSI-H) patients. Additionally, the guidelines offer detailed screening recommendations for hereditary gastric cancer and an appendix listing drug treatment regimens for various stages of gastric cancer. The 2023 CSCO Clinical Guidelines for Gastric Cancer updates are based on both Chinese and international clinical research and expert consensus to enhance their applicability and relevance in clinical practice, particularly in the heterogeneous healthcare landscape of China, while maintaining a commitment to scientific rigor, impartiality, and timely revisions | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Chinese Society of Clinical Oncology (CSCO) | |
| 650 | 4 | |a adjuvant | |
| 650 | 4 | |a chemotherapy | |
| 650 | 4 | |a diagnosis | |
| 650 | 4 | |a gastric cancer | |
| 650 | 4 | |a immunotherapy | |
| 650 | 4 | |a neoadjuvant | |
| 650 | 4 | |a radiotherapy | |
| 650 | 4 | |a surgery | |
| 650 | 4 | |a targeted therapy | |
| 700 | 1 | |a Zhang, Xiao-Tian |e verfasserin |4 aut | |
| 700 | 1 | |a Tang, Lei |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Qi |e verfasserin |4 aut | |
| 700 | 1 | |a Cai, Mu-Yan |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Yuan-Fang |e verfasserin |4 aut | |
| 700 | 1 | |a Qu, Xiu-Juan |e verfasserin |4 aut | |
| 700 | 1 | |a Qiu, Hong |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Yu-Jing |e verfasserin |4 aut | |
| 700 | 1 | |a Ying, Jie-Er |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Jun |e verfasserin |4 aut | |
| 700 | 1 | |a Sun, Ling-Yu |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, Rong-Bo |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Chang |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Hao |e verfasserin |4 aut | |
| 700 | 1 | |a Qiu, Miao-Zhen |e verfasserin |4 aut | |
| 700 | 1 | |a Guan, Wen-Long |e verfasserin |4 aut | |
| 700 | 1 | |a Rao, Sheng-Xiang |e verfasserin |4 aut | |
| 700 | 1 | |a Ji, Jia-Fu |e verfasserin |4 aut | |
| 700 | 1 | |a Xin, Yan |e verfasserin |4 aut | |
| 700 | 1 | |a Sheng, Wei-Qi |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Hui-Mian |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Zhi-Wei |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Ai-Ping |e verfasserin |4 aut | |
| 700 | 1 | |a Jin, Jing |e verfasserin |4 aut | |
| 700 | 1 | |a Yuan, Xiang-Lin |e verfasserin |4 aut | |
| 700 | 1 | |a Bi, Feng |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Tian-Shu |e verfasserin |4 aut | |
| 700 | 1 | |a Liang, Han |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Yan-Qiao |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Guo-Xin |e verfasserin |4 aut | |
| 700 | 1 | |a Liang, Jun |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Bao-Rui |e verfasserin |4 aut | |
| 700 | 1 | |a Shen, Lin |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Jin |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Rui-Hua |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer communications (London, England) |d 2018 |g 44(2024), 1 vom: 23. Jan., Seite 127-172 |w (DE-627)NLM28410809X |x 2523-3548 |7 nnns |
| 773 | 1 | 8 | |g volume:44 |g year:2024 |g number:1 |g day:23 |g month:01 |g pages:127-172 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/cac2.12516 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 44 |j 2024 |e 1 |b 23 |c 01 |h 127-172 | ||